Mirati Therapeutics, Inc. (MRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 36.50 |
| Open | 36.97 |
| Bid | 40.97 x 1100 |
| Ask | 40.99 x 1300 |
| Day's Range | 36.53 - 41.08 |
| 52 Week Range | 27.30 - 101.30 |
| Volume | |
| Avg. Volume | 1,186,322 |
| Market Cap | 2.866B |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Related Research
- Mirati Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
- PR Newswire
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
- PR Newswire
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- PR Newswire
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T. / 3:35 p.m. E.T. Ben Hickey, chief commercial officer, and Jamie Christensen, Ph.D., chief scientific officer, will represent the company in a fireside chat at the conference.
